Fingolimod (FTY720) prevents chronic rejection of rodent cardiac allografts through inhibition of the RhoA pathway
Abstract The Fingolimod (FTY720, Gilenya) is clinically approved for the treatment of
multiple sclerosis (MS). Its therapeutic effect on MS is based on the ability to bind
sphingosine 1-phosphate (S1P) receptors and block the exit of immune cells from the
lymphoid organs, thus preventing immune cell-dependent injury to the central nervous
system (CNS). We showed recently that, besides the S1P-related activity, the FTY720 also
down-regulates RhoA, which is a master regulator of the actin cytoskeleton. Our previous …
multiple sclerosis (MS). Its therapeutic effect on MS is based on the ability to bind
sphingosine 1-phosphate (S1P) receptors and block the exit of immune cells from the
lymphoid organs, thus preventing immune cell-dependent injury to the central nervous
system (CNS). We showed recently that, besides the S1P-related activity, the FTY720 also
down-regulates RhoA, which is a master regulator of the actin cytoskeleton. Our previous …
